JP2016523558A5 - - Google Patents

Download PDF

Info

Publication number
JP2016523558A5
JP2016523558A5 JP2016525289A JP2016525289A JP2016523558A5 JP 2016523558 A5 JP2016523558 A5 JP 2016523558A5 JP 2016525289 A JP2016525289 A JP 2016525289A JP 2016525289 A JP2016525289 A JP 2016525289A JP 2016523558 A5 JP2016523558 A5 JP 2016523558A5
Authority
JP
Japan
Prior art keywords
active ingredient
cell
peptide
cancer
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016525289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523558A (ja
JP6574175B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2014/006257 external-priority patent/WO2015005723A1/ko
Publication of JP2016523558A publication Critical patent/JP2016523558A/ja
Publication of JP2016523558A5 publication Critical patent/JP2016523558A5/ja
Application granted granted Critical
Publication of JP6574175B2 publication Critical patent/JP6574175B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016525289A 2013-07-12 2014-07-11 細胞透過性ペプチド、及びそれを含むコンジュゲート Active JP6574175B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20130082265 2013-07-12
KR10-2013-0082265 2013-07-12
KR20130165071 2013-12-27
KR10-2013-0165071 2013-12-27
PCT/KR2014/006257 WO2015005723A1 (ko) 2013-07-12 2014-07-11 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트

Publications (3)

Publication Number Publication Date
JP2016523558A JP2016523558A (ja) 2016-08-12
JP2016523558A5 true JP2016523558A5 (enExample) 2017-08-17
JP6574175B2 JP6574175B2 (ja) 2019-09-11

Family

ID=52280308

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016525289A Active JP6574175B2 (ja) 2013-07-12 2014-07-11 細胞透過性ペプチド、及びそれを含むコンジュゲート

Country Status (6)

Country Link
US (1) US9757473B2 (enExample)
EP (1) EP3020724A4 (enExample)
JP (1) JP6574175B2 (enExample)
KR (1) KR102224965B1 (enExample)
CN (1) CN105531284B (enExample)
WO (1) WO2015005723A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104507961B (zh) 2012-05-11 2018-08-14 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
EP3736282B1 (en) 2012-09-19 2023-06-21 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
EP2899201B1 (en) 2012-09-19 2019-09-11 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
EP3020724A4 (en) 2013-07-12 2017-01-18 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
EP3305802B1 (en) 2015-05-26 2021-05-12 Gemvax & Kael Co., Ltd. Anti-inflammatory, anti-fibrotic and wound-healing octapeptides and compositions containing the same
EP4332219B1 (en) * 2021-05-14 2026-02-18 Remedi Co., Ltd Cargo molecule tranduction domain rmad1, variant thereof, recombinant cargo molecule, and method for tranducing cargo molecule using same
US20240252660A1 (en) * 2021-06-03 2024-08-01 Remedi Co., Ltd. Cargo molecule transduction domain rmmr1, variant thereof, recombinant cargo molecule, and method for transducing cargo molecule using same
CN120958034A (zh) 2023-02-23 2025-11-14 微肽技术有限公司 用于产生和纯化肽的方法和组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100581990B1 (ko) * 1997-07-01 2006-05-23 캄비아 바이오시스템즈 엘엘씨 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
GB0114719D0 (en) * 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
US20030143228A1 (en) * 2001-10-29 2003-07-31 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen
US7101844B2 (en) * 2002-03-29 2006-09-05 Creagene, Inc. Cytoplasmic transduction peptides and uses thereof
US7294708B2 (en) * 2002-05-31 2007-11-13 Beijing Institute Of Biotechnology Telomerase reverse transcriptase fragments and uses thereof
CN101522706B (zh) * 2006-10-12 2013-09-04 P.安杰莱蒂分子生物学研究所 端粒酶逆转录酶融合蛋白、编码它的核苷酸以及其用途
KR101169030B1 (ko) * 2009-01-21 2012-07-26 애니젠 주식회사 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
KR101348284B1 (ko) 2010-09-09 2014-01-03 주식회사 나이벡 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
CN102321658A (zh) * 2011-07-20 2012-01-18 安徽农业大学 猪体细胞的重组蛋白诱变方法
KR101293620B1 (ko) * 2011-08-19 2013-08-13 국립암센터 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도
KR20130082265A (ko) 2012-01-11 2013-07-19 스키너스 주식회사 조적벽체 내진보강 구조
KR101444199B1 (ko) * 2012-02-20 2014-09-30 대한민국 세포막 투과용 단백질 및 그 용도
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
EP2899199B1 (en) * 2012-09-19 2019-07-03 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
EP3020724A4 (en) 2013-07-12 2017-01-18 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same

Similar Documents

Publication Publication Date Title
Natarajan et al. Sustained-release from nanocarriers: a review
US12370258B2 (en) PD-1 and CTLA-4 dual inhibitor peptides
CL2020000983A1 (es) Nuevo péptido de seq id no: 34 para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer (divisional de la solicitud no. 201701819)
JP2015530358A5 (enExample)
JP2016527286A5 (enExample)
CR20200557A (es) PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE MAMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0135)
EA201891994A1 (ru) Лечение рака матки
EA201992664A2 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
EA202191027A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
WO2016202963A3 (en) Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
SG10201807588TA (en) Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
HK1259376A1 (zh) 用於cll和其他癌症免疫治疗的新型肽和肽组合物
WO2017021527A3 (en) Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
WO2017005733A3 (en) Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
WO2012094653A4 (en) Compositions and methods for macromolecular drug delivery
PE20240778A1 (es) Nuevos peptidos y combinacion de peptidos para usar en inmuterapia contra el cancer esofagico y otros canceres
MX2018011388A (es) Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer.
HRP20230878T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raznih karcinoma (seq id 25 - mrax5-003)
JP2016530233A5 (enExample)
CR20200059A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres
Waeckerle-Men et al. Photochemical targeting of antigens to the cytosol for stimulation of MHC class-I-restricted T-cell responses
Li et al. DNA origami-based composite nanosandwich for iteratively potentiated chemo-immunotherapy
Mallick et al. Engineered vitamin E-tethered non-immunogenic facial lipopeptide for developing improved siRNA based combination therapy against metastatic breast cancer
UA124331C2 (uk) Пептид, здатний зв'язуватися з молекулою головного комплексу гістосумісності (mhc) людини i класу
Li et al. In situ cancer stem cell vaccination and immune activation enabled by CSC-specific ligand screening